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Metabolic control: A new solution to an old problem
D. Grahame Hardie
The phenomenon whereby the presence of oxygen
regulates the rate of glucose metabolism was first
described by Louis Pasteur. A novel mechanism has
now been discovered, involving the AMP-activated
protein kinase cascade, that can account for the
Pasteur effect in ischaemic heart muscle.
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In 1861 Louis Pasteur [1] reported that oxygen inhibits
fermentation, the production of ethanol by glycolysis in
yeast. The corollary of this is that anoxia, the absence of
oxygen, stimulates glycolysis. This phenomenon, which
occurs in mammalian cells as well as yeast, became known
as the ‘Pasteur effect’, and it took a whole century for the
first mechanism that can account for it to be elucidated.
Important clues came in the 1930s and 1940s, from studies
of mysterious deaths among workers who handled picric
acid (trinitrophenol) in the explosives industry, and who
suffered from acute elevation of body temperature. It
turned out that nitrophenols ‘uncouple’ phosphorylation
from respiration, allowing respiration to continue without
the resynthesis of ATP from ADP, the energy being dissi-
pated instead as heat. In the presence of these uncoupling
agents the Pasteur effect was found to be abolished, with
glycolysis occurring at a high rate in the presence or
absence of oxygen. 
With the benefit of hindsight, one obvious explanation of
the Pasteur effect is that the adenine nucleotides them-
selves control glycolysis. The final link was the finding
by Passonneau and Lowry [2] and others in the early
1960s that the glycolytic enzyme phosphofructokinase is
allosterically activated by AMP, and that this is
antagonized by high concentrations of ATP. At first sight
it might seem more logical for ADP, rather than AMP, to
regulate phosphofructokinase. But because of the near
equilibrium of the reaction catalysed by adenylate kinase
in most cells — 2ADP ↔ ATP + AMP — a small increase
in the ADP:ATP ratio is amplified into a much larger
increase in AMP:ATP ratio (if the adenylate kinase reac-
tion is at equilibrium, the AMP:ATP ratio will vary as the
square of the ADP:ATP ratio, making the former a much
more sensitive indicator of cellular energy status). This is
the ‘classical’ explanation for the Pasteur effect: in the
absence of oxygen, ATP production falls, the AMP:ATP
ratio rises and phosphofructokinase, and hence glycolysis,
will be stimulated.
Although more recent studies have shown that the control
of glycolysis is distributed across several steps, and is not
solely confined to phosphofructokinase, this remains the
explanation given in most textbooks and introductory
courses in biochemistry. While it remains valid, and may
indeed be a reasonably complete explanation for the
Pasteur effect in some cell types, in this issue of Current
Biology, Hue and coworkers [3] report a novel additional
mechanism to account for the Pasteur effect in ischaemic
heart muscle. 
In the early 1980s, Hue and others [4] discovered a new
allosteric activator of phosphofructokinase — fructose-2,6-
bisphosphate. Fructose-2,6-bisphosphate is formed from
fructose-6-phosphate and ATP (Figure 1) by an enzyme
called 6-phosphofructo-2-kinase. This enzyme catalyzes a
very similar reaction to phosphofructokinase, but attaches
the phosphate to carbon-2 of fructose-6-phosphate, rather
than carbon-1 (strictly, the glycolytic enzyme should be
called 6-phosphofructo-1-kinase). Fructose-2,6-bisphosphate
is not a metabolic intermediate but a signal molecule, the
only known fate of which is hydrolysis back to fructose-
6-phosphate, catalyzed by fructose-2,6-bisphosphatase.
Intriguingly, the 6-phosphofructo-2-kinase and fructose-
2,6-bisphosphatase reactions are catalyzed by distinct
domains of a single, bifunctional polypeptide. In mammals
this bifunctional enzyme occurs as at least four distinct iso-
forms that have distinct regulatory properties.
At this point a new player, the AMP-activated protein
kinase (AMPK) [5], enters the story. As well as phospho-
fructokinase, certain other metabolic enzymes, such as
glycogen phosphorylase, are also regulated by AMP, ADP
and/or ATP, and in the 1960s Daniel Atkinson [6] pro-
posed that most, if not all, branch points between
anabolism and catabolism might be controlled by these
nucleotides. This became known as the ‘adenylate control’
or ‘energy charge’ hypothesis. The latter term came from
the analogy between ATP and ADP and the chemicals in
an electrical cell or battery. A high ATP:ADP ratio repre-
sents a fully charged battery, while a low ratio represents a
discharged or ‘flat’ battery. Atkinson’s idea perhaps lost
some support during the 1970s and 1980s because, after
the first examples, few other metabolic enzymes were
found to be directly regulated by adenine nucleotides.
Nevertheless it can be argued that his proposal was correct,
but that he had not anticipated the complete mechanism
by which it operates.
AMPK now appears to be the primary sensor of cellular
energy charge [5], and most of the effects of ATP deple-
tion are probably mediated through this kinase pathway,
rather than through direct effects of adenine nucleotides
on proteins producing the final output. AMPK is phos-
phorylated and activated by at least one upstream kinase
(AMPKK), and increases in AMP activate this cascade
via a complex mechanism that makes it exquisitely sen-
sitive to small changes in the AMP:ATP ratio [7]. AMPK
is therefore activated by cellular stresses that either
inhibit ATP production — as do heat shock, uncouplers
or other metabolic poisons, deprivation of oxygen or
glucose — or stimulate ATP consumption — as exercise
does in muscle. The activated kinase switches on cata-
bolic pathways that generate ATP, while switching off
anabolic pathways and other processes that consume
ATP. It achieves this both acutely, via direct phosphory-
lation of metabolic enzymes, and chronically, via effects
on gene expression.
Hue’s group [3] has now identified a new target for AMPK:
the heart isoform of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase. AMPK phosphorylates this bifunc-
tional enzyme at a single site, serine 466, resulting in an
increase in the Vmax of the 6-phosphofructo-2-kinase
activity, without affecting the fructose-2,6-bisphos-
phatase activity. A mutant form of the enzyme, S466E, in
which serine 446 is replaced by a negatively charged glu-
tamate, mimicking phosphorylation, is constitutively
active and is not a substrate for AMPK. The sequence
around serine 466 is a reasonable, if not exact, fit to the
proposed consensus recognition motif for AMPK sub-
strates [8], and the site appears to be phosphorylated with
kinetic parameters only slightly inferior to those of acetyl-
CoA carboxylase, an established physiological substrate.
Marsin et al. [3] went on to show that this phosphorylation is
physiologically relevant and occurs in the heart during
ischaemia — interruption of the blood supply to the heart
muscle, which is what happens during a heart attack.
AMPK is transiently activated by ischaemia in isolated,
perfused rat hearts, peaking at 10-fold activation after
10 minutes, and then declining over the next 20 minutes.
Given that ischaemia is known to cause elevation of the
AMP:ATP ratio in the heart, this effect is not surprising,
although the reason for its transient nature remains unclear.
It may be that after prolonged, severe ischaemia the ATP
levels become so low that they can no longer support the
ATP requirement of the AMPK cascade itself. Marsin et al.
[3] also found that the AMPK activation correlates excel-
lently with transient three-fold increases in both 6-phos-
phofructo-2-kinase activity and the cellular content of its
product, fructose-2,6-bisphosphate. This also correlates
with previous studies on the rate of glycolysis, which during
prolonged ischaemia is also transiently activated, followed
by a marked decline. It should be emphasized that AMPK
activation has also been reported to stimulate translocation
of the glucose transporter GLUT-4 to the plasma mem-
brane and consequent glucose uptake in heart [9], and this
effect may also contribute to the stimulation of glycolysis.
The new mechanism was further tested [3] using
transfected HEK-293 cells expressing the heart isoform
of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Activation of endogenous AMPK using the respiratory
chain inhibitor oligomycin resulted in a two-fold activation
of 6-phosphofructo-2-kinase, but not of an S466E mutant
form of the enzyme. Expression of a kinase-inactive
mutant form of the α1 subunit of AMPK blocked the
effect of oligomycin on both activation of 6-phosphofructo-
2-kinase and the phosphorylation of serine 466. In these
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Figure 1
Mechanism of activation of glycolysis by
AMP-activated protein kinase (AMPK) in heart
muscle. Inhibition of respiration by hypoxia or
oligomycin in turn inhibits the synthesis of
ATP from ADP + Pi. As contraction of the
heart, converting ATP to ADP + Pi, continues,
the ADP:ATP ratio will rise. This is amplified
into a larger rise in the AMP:ATP ratio by
adenylate kinase, and this in turn activates
AMPK via the established mechanism [7].
AMPK phosphorylates 6-phosphofructo-
2-kinase (6PF2K) leading to an increase in
fructose-2,6-bisphosphate (F26BP). This
signal stimulates phosphofructokinase and
hence glycolysis — the Pasteur effect —
resulting in anaerobic production of ATP to
meet the shortfall. Glycolysis is also
stimulated due to effects of AMPK on GLUT4
translocation [9]. Black text is reserved for
metabolites (the names of enzymes and other
proteins are shown in blue); the black arrows
represent metabolic transformations; green
and red arrows represent regulatory circuits,
green for activation and red for inhibition.
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cells, the kinase-inactive form of AMPK appears to act as a
dominant-negative mutant — probably by competing for
the regulatory β and γ subunits of AMPK — because it
also blocked activation of both endogenous and trans-
fected AMPK by oligomycin. This shows that activation of
AMPK is necessary, as well as sufficient, for the effect of
oligomycin on 6-phosphofructo-2-kinase.
The liver and skeletal muscle isoforms of 6-phosphofructo-
2-kinase/fructose-2,6-bisphosphatase lack the carboxy-ter-
minal sequence with the consensus AMPK site, so this
mechanism would only be expected to operate in cells
expressing the heart isoform — heart and kidney. This
perhaps makes sense in liver, where fructose-2,6-bis-
phosphate also regulates gluconeogenesis, and where gly-
colysis can be regarded as an anabolic rather than a catabolic
pathway (for example, it provides precursors for lipid
biosynthesis). It is less clear, however, why this mechanism
should not operate in skeletal muscle. Glucose uptake is
still activated by AMPK in that tissue, and 6-phosphofructo-
1-kinase would still be allosterically regulated by AMP and
ATP (the classical explanation for the Pasteur effect).
Perhaps those controls are sufficient in skeletal muscle.
Finally, in the 1920s Warburg reported that many tumour
cells have a high rate of glycolysis (tumours often having a
poor blood supply in vivo). Some tumours overexpress a
placental isoform of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase [10] in which the AMPK phosphoryla-
tion site is conserved. Although they did not test the
placental enzyme itself, Marsin et al. [3] did examine a
synthetic peptide based on this sequence, which was
indeed a substrate for AMPK. This raises the intriguing
possibility that AMPK, and its phosphorylation of 6-phos-
phofructo-2-kinase/fructose-2,6-bisphosphatase, could be
helping to keep some hypoxic tumours alive until they
have established a new blood supply.
Acknowledgements
Studies on AMP-activated protein kinase in this laboratory are supported by
the Wellcome Trust, Diabetes UK, and the Medical Research Council.
References
1. Pasteur L: Expériences et vues nouvelles sur la nature des
fermentations. Comp Rend Acad Sci 1861, 52:1260-1264.
2. Passonneau JV, Lowry OH: Phosphofructokinase and the Pasteur
effect. Biochem Biophys Res Commun 1962, 7:10-15.
3. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Françoise
Vincent M, Van den Berghe G, Carling D, Hue L: Phosphorylation
and activation of heart PFK-2 by AMPK has a role in the
stimulation of glycolysis during ischaemia. Curr Biol 2000,
10:1247-1255.
4. Hue L, Rider MH: Role of fructose 2,6-bisphosphate in the control
of glycolysis in mammalian tissues. Biochem J 1987,
245:313-324.
5. Hardie DG, Carling D, Carlson M: The AMP-activated/SNF1 protein
kinase subfamily: metabolic sensors of the eukaryotic cell? Annu
Rev Biochem 1987, 67:821-855.
6. Ramaiah A, Hathaway JA, Atkinson DE: Adenylate as a metabolic
regulator. Effect on yeast phosphofructokinase kinetics. J Biol
Chem 1964, 239:9619-9622.
7. Hardie DG, Salt IP, Hawley SA, Davies SP: AMP-activated protein
kinase: an ultrasensitive system for monitoring cellular energy
charge. Biochem J 1999, 338:717-722.
8. Dale S, Wilson WA, Edelman AM, Hardie DG: Similar substrate
recognition motifs for mammalian AMP-activated protein kinase,
higher plant HMG-CoA reductase kinase-A, yeast SNF1, and
mammalian calmodulin-dependent protein kinase I. FEBS Lett
1995, 361:191-195.
9. Russell RR 3rd, Bergeron R, Shulman GI, Young LH: Translocation
of myocardial GLUT-4 and increased glucose uptake through
activation of AMPK by AICAR. Am J Physiol 1999, 277:H643-649.
10. Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y,
Han JH, Metz C, Bucala R: An inducible gene product for 6-
phosphofructo-2-kinase with an AU-rich instability element: role
in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci
USA 1999, 96:3047-3052.
Dispatch R759
